News & Events

Learn about what's new with CMC Biologics

AGC to Complete the Acquisition of MolMed on July 31, 2020

News

AGC Biologics adds leading-edge cell & gene therapy company in Milan, Italy

(SEATTLE), July 27, 2020 -- AGC Biologics, a Global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced that they will acquire the majority of the share capital of Molecular Medicine S.p.A. ("MolMed") on July 31, 2020. MolMed is a biotechnology company focused on research, development, production and clinical validation of cell and gene therapies for the treatment of cancer and rare diseases. AGC Biologics is now one of the very few CDMO’s in the world offering both plasmid production and end-to-end cell and gene therapy services.


AGC Biologics Collaborates with Molecular Partners AG to Develop Anti-COVID-19 DARPin® Program

News

(SEATTLE), July 9, 2020 -- Global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO) AGC Biologics is partnering with clinical-stage biotech company Molecular Partners AG to develop a new class of custom-built protein therapeutics known as DARPin®. AGC Biologics and Molecular Partners AG will work together to develop their multi-specific DARPin anti-COVID-19 program, MP0420. Molecular Partners AG plans to initiate clinical studies for this program in the second half of 2020.

Follow Us
Join us on LinkedIn Follow us on Twitter